



EUROPEAN MEDICINES AGENCY  
SCIENCE MEDICINES HEALTH

# Webinar on the use of platform approaches in the non-clinical and clinical domains - agenda

2 March 2026, 9:25 – 12:30 (CET)

**Virtual meeting**

The proposal for the EU pharmaceutical legislation introduces the concepts of platform technologies and platform marketing authorisation.

The European Medicines Agency organises a webinar bringing together regulators and medicine developers to discuss the use of platform approaches (platform marketing authorisation and platform technologies) beyond the quality and manufacturing domains.

The main objectives of the webinar are:

- Clarifying the current EU legal framework for the development and marketing of individualised therapies (n=1) and for the use of prior knowledge in Marketing Authorisation dossiers;
- Presenting case studies on the use of platform approaches in the non-clinical and clinical domains and exploring their possible applications and values;
- Discussing the challenges and identify opportunities related to the use of platform approaches;
- Facilitating the implementation of the EU pharmaceutical legislation provisions on platform technologies and platform marketing authorisation.

# Webinar on the use of platform approaches in the non-clinical and clinical domains - agenda

Co-chairs: Falk Ehmann (EMA) and Oriane Blanquie (EMA)

## Monday 2 March 2026, 09:25 – 12:30 (CET)

### 09:00 Joining and technical checks

---

### 09:25 Welcome and opening speech

---

*Steffen Thirstrup (EMA)*

**5 min**

### 09:30 Session 1: Leveraging platform approaches in the development of therapies in the EU

---

#### **Current regulatory routes for individualised therapies**

**15 min**

*Ilona Reischl-Kok (AGES-MEA, CAT chair)*

#### **Regulatory experience on the use of prior knowledge and platform approaches**

**15 min**

*Ragini Shivji (EMA)*

*Javier Pozo Gonzalez (EMA)*

#### **Provisions of the new EU Pharmaceutical Legislation on platform approaches**

**15 min**

*Florian Schmidt (European Commission)*

#### **Q&A session**

**15 min**

### 10:30 Coffee break

---

### 10:40 Session 2: Non-clinical and clinical case studies

---

#### **Stakeholder perspectives on the implementation of platform technology in the EU regulation: results from a focus group study**

**15 min**

*Stephanie Oskam (Utrecht University, CBG-MEB)*

#### **Case 1 (academia)**

**15 min**

*Annemieke M. Aartsma-Rus (Leiden University Medical Center)*

#### **Case 2 (large pharma)**

**15 min**

*Mihai Bilanin (EFPIA, Vaccines Europe)*

**Case 3 (small and mid-sized enterprises)**

*Alexander Natz (EUCOPE)*

**15 min**

**11:40**

**Session 3: Panel discussion**

---

*All speakers, Marjon Pasmooij (CBG-MEB, Utrecht University)  
and Thomas Girard (EMA)*

**45 min**

**12:25**

**Closing remarks**

---

**Wrap up**

*Falk Ehmann (EMA)*

**5 min**